AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP announced a class action has been filed against Aardvark Therapeutics (NASDAQ: AARD) for investors who bought shares in the Feb. 13, 2025 IPO and/or between Feb. 13, 2025 and May 14, 2026. The news is a litigation overhang for a clinical-stage biopharma, which can raise downside risk to equity sentiment even without quantified financial damage yet.

Analysis

This is less about near-term legal liability and more about financing optionality. For a clinical-stage issuer, any disclosure-driven class action tends to raise the equity risk premium exactly when the company is most dependent on external capital, so the first-order hit is usually to multiple and secondary-offer capacity rather than to operating income. The market often underestimates the second-order effect: even a nuisance case can force a bigger dilution discount at the next raise, which matters more than eventual settlement size.

The immediate window is days to weeks, when headline-driven holders and IPO-flip shareholders de-risk. The more important catalyst path is 1-3 months, when lead-plaintiff selection and amended complaints keep the overhang alive; that period usually compresses rebounds and suppresses momentum in comparable pre-revenue biotech IPOs. If AARD has a limited cash runway, this becomes a structural issue over 6-18 months because litigation plus clinical spend can push management toward a financing done from weakness.

The contrarian view is that the market may already view these suits as boilerplate and overreact only if there is a credible claim of bad disclosure rather than simply a stock drawdown. If the company subsequently posts clean trial updates or improves cash guidance, the lawsuit becomes noise and the selloff should mean-revert. Falsifiers: dismissal early in the process, D&O insurance coverage that is clearly sufficient, or a material positive clinical readout that re-rates the name despite the legal overhang.

Key Decisions for Investors

• Avoid initiating fresh long exposure in AARD for the next 1-3 months; any bounce is likely to face litigation overhang and weaker secondary-offer terms.
• If borrow/liquidity are workable, short AARD on relief rallies rather than into the open; target a 2-4 week window around complaint/lead-plaintiff headlines with a tight risk limit.
• Use XBI as a hedge for broader biotech beta if you are forced to hold AARD exposure; this is primarily a single-name discount-rate issue, not a sector-wide fundamental shock.
• Watch the next financing/cash-runway update as the real catalyst; if management needs capital within 2-3 quarters, the lawsuit becomes a stronger bearish catalyst.
• If the stock drops sharply on the headline without any liquidity or runway deterioration, treat it as a potential overreaction and cover into panic rather than press the short.